Inventors:
Michael J. MANN - San Francisco CA, US
David M. Jablons - San Francisco CA, US
Johannes Kratz - Cambridge MA, US
David M. Berryman - Foster City CA, US
Assignee:
Pinpoint Genomics, Inc. - Mountain View CA
The Regents of the University of California - Oakland CA
International Classification:
C40B 30/04, C40B 40/10, C40B 40/06
Abstract:
The present invention provides methods for providing a prognosis for lung cancer using a panel of eleven molecular markers that includes BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, and WNT3A, which are differentially expressed in lung cancer. The eleven markers are related to patient prognosis to 5-year overall survival outcomes, and are particularly useful in providing a prognosis for non-squamous NSCLC.